Context: Several previous studies have investigated circulating levels of the adipokine leptin in relation to gestational diabetes mellitus (GDM). However, these studies have yielded markedly conflicting results, including increased, decreased, and unchanged leptin levels in women with GDM as compared with their peers.
L
eptin is an adipocyte-secreted hormone (adipokine) with pleiotropic bioactivity, including effects on regulation of body weight, energy homeostasis, reproduction, and immune function (1, 2) . Although it has been proposed as a biomarker of diabetic risk, studies of leptin as a predictor of type 2 diabetes have yielded variable results (3) (4) (5) (6) (7) (8) . The relationship between leptin and gestational diabetes mellitus (GDM) remains similarly unclear because, although several previous studies have investigated leptin levels in GDM, they have yielded markedly conflicting results. Indeed, whereas many studies have reported antepartum leptin levels to be higher in women with GDM than in their peers (9 -15) , others have found no difference (16 -18) . Moreover, some studies have even reported lower leptin concentrations in women with GDM compared with their peers (19, 20) . Importantly, it should be noted that these studies have been limited by 1) modest numbers of women with GDM, 2) heterogeneity in the glucose tolerance status of comparators, and 3) varying degrees of adjustment for potential confounders. Thus, hypothesizing that these limitations have contributed to this inconclusive literature, our objective was to evaluate the metabolic determinants of serum leptin in a large cohort of women reflecting the full spectrum of glucose intolerance in pregnancy, with adjustment for a broad array of potential covariates.
Subjects and Methods

Study population
This analysis was conducted as part of an ongoing cohort study in which pregnant women are recruited at the time of antepartum screening for GDM (21) . The study protocol was approved by the Mount Sinai Hospital Research Ethics Board and has been described in detail previously (21, 22) . In brief, all participants undergo a 3-h 100-g oral glucose tolerance test (OGTT) in late second/early third trimester and simultaneous metabolic characterization consisting of interviewer-administered questionnaires, physical examination, and assessment of cardiometabolic risk factors. As previously described, the OGTT enables stratification of participants into the following three gestational glucose tolerance categories: 1) GDM (defined by exceeding at least two glycemic thresholds on the OGTT, as defined by National Diabetes Data Group criteria); 2) gestational impaired glucose tolerance (GIGT, defined by exceeding one National Diabetes Data Group glycemic threshold); or 3) normal glucose tolerance (NGT). All participants provided written informed consent. The current analysis was restricted to women with singleton pregnancies (n ϭ 817).
Laboratory measurements
All OGTT were performed in the morning after an overnight fast. During the OGTT, venous blood samples were drawn for measurement of glucose and insulin at fasting and at 30, 60, 120, and 180 min after ingestion of the glucose load. The area under the glucose-curve during the OGTT (AUC glucose ) was calculated by trapezoidal rule, thereby providing a continuous measure of glycemia to complement the categorical glucose tolerance status defined 
Statistical analyses
All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC). In Table 1 , data are presented as mean (SD) for normally distributed continuous variables and as median (interquartile range) for skewed variables. Natural log transformations were used in subsequent analyses of skewed variables, where necessary. The 2 tests (categorical variables) and ANOVA (continuous variables) were used to determine differences across the three glucose tolerance categories in pregnancy. Univariate correlations between leptin and continuous variables were assessed by Spearman correlation analysis (Table 2) . Multiple linear regression analysis was performed to determine independent relationships between antepartum characteristics and dependent variable leptin (Table 3) . Covariates included in this analysis consisted of demographic/clinical variables (age, ethnicity, and family history of diabetes), reproductive factors (parity, previous GDM, and weeks gestation at OGTT), and metabolic factors [prepregnancy BMI, gestational weight gain up to the OGTT, AUC glucose , fasting insulin, LDL, HDL, triglycerides, CRP, and adiponectin]. Owing to the significant interactions of metabolic variables (AUC glucose , fasting insulin, and adiponectin) with prepregnancy BMI, the multiple linear regression analyses were repeated after stratification of the study population into tertiles of pregravid BMI (Table 4 ). Table 1 shows the characteristics of the study population stratified into the following three gestational glucose tolerance groups: NGT (n ϭ 477), GIGT (n ϭ 142), and GDM (n ϭ 198). There were no significant differences between the groups in age or parity. The antepartum OGTT was performed slightly earlier in women with GDM (median 29 wk compared with 30 wk in the other two groups; overall P ϭ 0.014). As expected, there were significant differences between the three glucose tolerance groups in GDM risk factors (ethnicity, family history of diabetes, previous GDM, prepregnancy BMI) and metabolic variables (AUC glucose , fasting insulin, HDL cholesterol, triglycerides, CRP, and adiponectin). However, there was no significant difference in leptin concentration across the gestational glucose tolerance groups (P ϭ 0.085).
Results
On Spearman univariate correlation analysis (Table 2) , leptin was most strongly associated with prepregnancy BMI (r ϭ 0.54, P Ͻ 0.0001), fasting insulin (r ϭ 0.60, P Ͻ 0.0001), CRP (r ϭ 0.38, P Ͻ 0.0001), adiponectin (r ϭ Ϫ0.24, P Ͻ 0.0001), and gestational weight gain up to the OGTT (r ϭ 0.15, P Ͻ 0.0001). However, leptin was only weakly associated with AUC glucose (r ϭ 0.10, P ϭ 0.0066). Weak inverse associations with LDL (r ϭ Ϫ0.09, P ϭ 0.0088) and age (r ϭ Ϫ0.07, P ϭ 0.042) were also noted.
On multiple linear regression analysis (Table 3) , a model consisting of age, weeks gestation, ethnicity, family history of diabetes, parity, previous GDM, prepregnancy BMI, gestational weight gain, AUC glucose , fasting insulin, LDL, HDL, triglycerides, CRP, and adiponectin explained 51.4% of the variance associated with dependent variable leptin. This analysis revealed that the strongest indepen- dent determinant of leptin was prepregnancy BMI (t ϭ 11.55, P Ͻ 0.0001). Other significant covariates were fasting insulin (t ϭ 9.97, P Ͻ 0.0001), gestational weight gain up to the OGTT (t ϭ 9.30, P Ͻ 0.0001), CRP (t ϭ 6.48, P Ͻ 0.0001), parity of at least one (t ϭ Ϫ4.98, P Ͻ 0.0001), ethnicity other than Caucasian or Asian (t ϭ 3.43, P ϭ 0.0006), and triglycerides (t ϭ Ϫ2.68, P ϭ 0.0076). Repeating this multiple linear regression analysis with categorical glucose tolerance status (NGT, GIGT, and GDM) as a covariate in place of AUC glucose yielded the very same significant predictors, with neither GDM (t ϭ Ϫ1.23, P ϭ 0.22) nor GIGT (t ϭ Ϫ0.81, P ϭ 0.42) emerging as independent covariates of leptin (data not shown). On testing the model in Table 3 for interactions between covariates, we found significant interactions between prepregnancy BMI and each of the following variables: AUC glucose (interaction P ϭ 0.0004), fasting insulin (interaction P Ͻ 0.0001), and adiponectin (interaction P Ͻ 0.0001). In light of these findings, we stratified the study population into tertiles of prepregnancy BMI and repeated the multiple linear regression models within each of these three groups (Table 4 ). These analyses revealed that prepregnancy BMI, gestational weight gain, fasting insulin, CRP, and parity were independently associated with leptin within each BMI tertile. In contrast, the significant associations between leptin and ethnicity and triglycerides and adiponectin, respectively, were found in only certain tertiles. Figure 1 shows examples of different patterns of effect modification by prepregnancy BMI on the metabolic correlates of antepartum leptin. First, as shown in Fig. 1A , AUC glucose was not significantly associated with leptin in any BMI tertile, although it may be trending toward a weak inverse relationship in the heaviest women (third tertile). In contrast, although fasting insulin was significantly correlated with leptin in all three tertiles (Fig. 1B) , the magnitude of this association was far greater in the leanest women (␤ ϭ 0.53) than in the middle or heaviest tertiles (␤ ϭ 0.33 and ␤ ϭ 0.21, respectively). Third, triglyceride level (Fig. 1C) was inversely associated with leptin in the leanest women (␤ ϭ Ϫ0.17, P ϭ 0.001) but not at all related in the middle (␤ ϭ Ϫ0.04, P ϭ 0.35) and highest (␤ ϭ Ϫ0.06, P ϭ 0.19) tertiles. Lastly, adiponectin (Fig. 1D) was significantly correlated with leptin in only the middle tertile of prepregnancy BMI (␤ ϭ 0.03, P ϭ 0.035).
As a supplemental analysis, the multiple linear regression models of leptin were repeated after stratifying the study population into the following three groups based on prepregnancy BMI: 1) BMI below 25 kg/m 2 (n ϭ 512); 2) BMI between 25.0 and 29.99 kg/m 2 inclusive (n ϭ 183); and 3) BMI 30.0 kg/m 2 or higher (n ϭ 122). These analyses showed that, as with the tertile analysis in Table 4 , prepregnancy BMI and gestational weight gain up to the OGTT were positive independent predictors of leptin in each of the three groups, whereas AUC glucose was not associated with leptin in any group, and other variables had group-specific associations that varied according to the prepregnancy BMI group (Supplemental Table 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
Discussion
Previous reports of antepartum serum leptin in GDM have been conflicting; several studies have reported higher leptin levels in GDM than in NGT controls (9 -13), whereas others have reported lower leptin levels in GDM than controls after adjusting or matching for BMI (19, 20) , and finally, other studies have reported no difference in leptin concentration between participants with and without
FIG. 1.
Adjusted relationships between log leptin and AUC glucose (A), log fasting insulin (B), triglycerides (C), and adiponectin (D) within each tertile of prepregnancy BMI. Each relationship is adjusted for the following covariates: age, weeks gestation, ethnicity, family history of diabetes, parity, previous GDM, prepregnancy BMI, gestational weight gain up to the OGTT, AUC glucose , fasting insulin, LDL, HDL, triglycerides, CRP, and leptin.
GDM (16 -18) , including after adjustment for BMI (23) . However, there are important limitations of this literature that are likely contributing to these conflicting results. First, these studies have had relatively modest numbers of women with GDM (generally between 50 and 60), with the largest reporting only 63 such patients. Second, the gestational glucose tolerance status of the comparator women (i.e. the group against which GDM has been compared) has varied. Specifically, some studies compared the levels of leptin in GDM against those in women with confirmed NGT, whereas other studies defined the comparator group by the absence of GDM (i.e. which could include gestational glucose intolerance). Third, the previous studies have varied in the extent of their adjustment for covariates, an important issue given the relationships between leptin and numerous metabolic variables. Thus, in light of these limitations, our study aimed to reconcile the previously reported conflicting data through the following design features: 1) assessment of more than three times as many participants with GDM than any of the previous studies, 2) evaluation across the full range of gestational glucose tolerance status, and 3) adjustment for a broad array of metabolic variables. Bolstered by these strengths in study design, our data demonstrate that there is no significant independent relationship between glucose tolerance status in pregnancy and maternal serum leptin levels. The robustness of this finding is supported by the fact that the regression models explained a high proportion of the variance in leptin concentration (e.g. model adjusted R 2 ϭ 51.4% in Table 3 ) and identified several independent determinants thereof, but neither AUC glucose nor GDM was one of them. Instead, we found that prepregnancy BMI is the primary determinant of leptin levels in pregnancy. Leptin is produced by adipocytes, is elevated in obese women, and correlates with BMI and body fat percentage in the setting of pregnancy and GDM (9, (23) (24) (25) . Although placental production likely contributes to the rise in circulating leptin levels that takes place in pregnancy, it has recently been suggested that the overall impact of this placental contribution is modest (26) . Indeed, consistent with this suggestion, we found that pregravid BMI was a much stronger determinant of antepartum leptin concentration than was gestational weight gain and that weeks gestation was not a significant predictor (Tables 2 and 3 ). Thus, placental contribution notwithstanding, the current data emphasize the dominant role of prepregnancy BMI in determining the absolute levels of serum leptin in late pregnancy.
Furthermore, we have also demonstrated that prepregnancy BMI modifies the associations of leptin with various metabolic factors. As demonstrated in Fig. 1 , the impact of prepregnancy BMI on the relationships between leptin and cardiometabolic risk factors is complex and varied. Indeed, triglycerides were inversely associated with leptin in only the lowest tertile of pregravid BMI, whereas adiponectin was positively correlated in only the middle tertile. Conversely, although the significance of their associations with leptin did not change between tertiles, both fasting insulin and AUC glucose exhibited significant interactions with prepregnancy BMI. Specifically, the magnitude of the association beween leptin and fasting insulin decreased as pregravid BMI rose, whereas AUC glucose showed a nonsignificant trend toward an inverse relationship with leptin in the heaviest tertile that was not at all apparent in the other two tertiles. Importantly, our findings emerge only after BMI stratification and covariate adjustment in a very large sample size across a broad range of glucose tolerance in pregnancy. This previously unrecognized aspect of leptin physiology in pregnancy could have also contributed to the earlier conflicting findings in the literature and again underscores the central importance of prepregnancy BMI.
Other independent covariates in the multiple regression analysis of maternal leptin in the current study included ethnicity other than Asian or Caucasian, parity of at least one, and CRP. Although there was no dominant ethnic group within the other category, ethnic differences in leptin levels have been previously reported (27) . The basis for the inverse association between parity of at least one and leptin is not clear but potentially may relate to the physiological effects of leptin on reproductive function (28) . Finally, it has previously been demonstrated that physiological concentrations of serum leptin can stimulate hepatocyte expression of CRP and that CRP can bind to leptin (as a serum leptin-interacting protein) (29) . In doing so, CRP can block the binding of leptin to its receptors and thereby induce target tissue insensitivity to the biological effects of leptin (i.e. leptin resistance) (29) . In this context, the current study confirms that an independent association exists between leptin and CRP in pregnancy and is consistent across BMI categories.
Although the current study demonstrates that maternal adiposity (rather than glucose intolerance) is the primary determinant of the circulating leptin concentration in pregnancy, the physiological implications of this relationship remain to be determined. Interestingly, we and others have demonstrated that, after adjustment for BMI, maternal serum leptin is inversely associated with infant birth weight (30, 31) . These data raise the possibility that, in pregnancy, leptin may play a role in attenuating the promacrosomic effects of maternal obesity. Ultimately, more longitudinal study is needed to evaluate the long-term implications of antepartum leptin on outcomes for both mother and child. With respect to the effects on the offspring, it is of interest that maternal glycemia has recently been associated with epigenetic modification of the leptin gene on the fetal side of the placenta (26) . Thus, although our study demonstrates that gestational dysglycemia does not affect serum leptin levels in pregnancy, it still may be relevant to long-term leptin physiology in the offspring. This study is limited by its observational nature and thus cannot examine causal relationships between leptin, maternal BMI, and cardiometabolic risk factors. Second, this cross-sectional analysis cannot provide insight on the relationships between these variables over the course of pregnancy. Third, the mechanisms underlying the apparent modifying effect of prepregnancy BMI are unclear, although leptin resistance is a recognized phenomenon in other settings (29, 32) . Nevertheless, through its evaluation of the complex relationships between leptin and an array of metabolic factors in a large cohort of women across the full spectrum of glucose tolerance in pregnancy, the current study has provided a potential reconciliation of the existing conflicting literature on leptin in GDM that should lead to additional studies.
In conclusion, we have reported that maternal antepartum leptin levels do not differ significantly across categories of gestational glucose tolerance. Instead, prepregnancy BMI is a key driver of maternal leptin levels and modifies the relationships between leptin and several key cardiometabolic risk factors. With this understanding, longitudinal studies are now required to assess the role of leptin in pregnancy and its implications for long-term metabolic risk of mother and offspring.
